Tesamorelin
Also known as: TH9507 · Egrifta · Egrifta SV · Tesamorelin acetate
Tesamorelin binds and activates GHRH receptors on pituitary somatotrophs with high affinity, stimulating pulsatile GH secretion. Unlike shorter GHRH fragments (CJC-1295), it uses the full 44-amino acid binding domain for maximum receptor occupancy. The N-terminal trans-3-hexenoic acid modification prevents DPP-IV...
What It Is
Tesamorelin binds and activates GHRH receptors on pituitary somatotrophs with high affinity, stimulating pulsatile GH secretion. Unlike shorter GHRH fragments (CJC-1295), it uses the full 44-amino acid binding domain for maximum receptor occupancy. The N-terminal trans-3-hexenoic acid modification prevents DPP-IV degradation for enhanced half-life. Clinical studies demonstrate significant reduction in visceral adipose tissue (VAT) in HIV patients via increased lipolysis. Tesamorelin also improves lipid profiles, reduces triglycerides, and improves insulin-like growth factor-1 (IGF-1) levels to high-normal physiological range.
Supplies Needed
Reconstitution solvent for multi-use stability
Subcutaneous injection
Sterilization
Storage
Store at 2-8C (refrigerator) - Egrifta requires refrigeration even lyophilized. Do not freeze.
Use within 3 hours per FDA prescribing information for Egrifta. Stable longer when reconstituted with bacteriostatic water (up to 30 days refrigerated).
This information is provided for educational and research purposes only. Not approved for human consumption by the FDA or any regulatory body. Always consult a qualified medical professional.
Dosing Protocols
Timing: Bedtime, fasted. This is the FDA-approved dose for HIV lipodystrophy; same dose used in non-FDA indications
↓ Apply these values to the reconstitution calculatorTiming: Bedtime, fasted. Clinical trials used 2 mg/day for body composition benefits; rotate injection sites
↓ Apply these values to the reconstitution calculatorTiming: Bedtime, fasted. Long-term use for sustained body composition benefits; monitor IGF-1 and blood glucose every 6 months
↓ Apply these values to the reconstitution calculatorWeekly Timeline
| Week | Expected Effects |
|---|---|
| Week 1 | GH pulsatility increases; mild water retention possible; improved energy |
| Week 4 | Early reduction in waist circumference; improved body composition markers |
| Week 12 | Significant VAT reduction (average 10-15%); improved triglycerides; better body composition |
| Week 26 | Maximum visceral fat reduction effect (~15-20%); sustained IGF-1 elevation in high-normal range |
Reconstitution Calculator
1 unit on U-100 syringe = 0.01 mL · Always label your vial after reconstitution
Injection Technique & Reconstitution
- Remove flip-top cap from the vial
- Swab rubber stopper with alcohol swab and allow to dry
- Draw sterile water for injection or bacteriostatic water into syringe per manufacturer instructions
- Inject slowly down the side of the vial wall
- Gently roll the vial between palms - do not shake
- Inject immediately; Egrifta should be used within 3 hours of reconstitution
- Rotate injection sites in the abdominal area
Use our free calculate your Tesamorelin dose to get the exact syringe units for your vial size and dose.
Mechanism of Action
Tesamorelin binds and activates GHRH receptors on pituitary somatotrophs with high affinity, stimulating pulsatile GH secretion. Unlike shorter GHRH fragments (CJC-1295), it uses the full 44-amino acid binding domain for maximum receptor occupancy. The N-terminal trans-3-hexenoic acid modification prevents DPP-IV degradation for enhanced half-life. Clinical studies demonstrate significant reduction in visceral adipose tissue (VAT) in HIV patients via increased lipolysis. Tesamorelin also improves lipid profiles, reduces triglycerides, and improves insulin-like growth factor-1 (IGF-1) levels to high-normal physiological range.
Key Research Papers
Phase 3 pivotal trial demonstrating significant VAT reduction, improved lipid profiles, and maintained lean body mass in HIV patients treated with Tesamorelin 2 mg daily.
View on PubMed →Demonstrated significant body composition improvements including visceral fat reduction in non-HIV adults with abdominal obesity.
View on PubMed →Stacks Well With
GHRH analog (Tesamorelin) + GHS-R1a agonist (Ipamorelin) produces synergistic GH release - same dual-pathway mechanism as CJC-1295/Ipamorelin but with Tesamorelin's stronger visceral fat reduction.
Combined approach to visceral fat reduction - Tesamorelin stimulates GH for systemic VAT reduction while AOD-9604 directly activates beta-adrenergic lipolysis.
Frequently Asked Questions
Tesamorelin is FDA-approved as Egrifta for reducing excess visceral fat (lipodystrophy) in HIV-infected patients on antiretroviral therapy. It is also used off-label for body composition improvement and anti-aging in non-HIV patients.
In clinical trials, Tesamorelin 2 mg daily reduced visceral adipose tissue (VAT) by an average of 15-20% over 26 weeks. This is the most clinically validated GHRH peptide for body composition improvement.
Tesamorelin uses the full GHRH(1-44) sequence vs CJC-1295's truncated 1-29 fragment, providing stronger receptor engagement. However, both stimulate pulsatile GH release. Tesamorelin has much stronger clinical evidence for visceral fat reduction.
Legal Status by Region
This information is provided for educational and research purposes only. Not approved for human consumption by the FDA or any regulatory body. Always consult a qualified medical professional.